Vertex Pharmaceuticals Announces $10 Billion Acquisition of Crinetics Pharmaceuticals
Vertex Pharmaceuticals has announced a $10 billion acquisition of early-stage biotech company Crinetics Pharmaceuticals. The deal is expected to close in Q3 and could add up to $5 billion annually in revenue through promising drug assets like Palsonify, potentially boosting Vertex's growth trajectory.
Topics: growth strategy M&A pharmaceuticals